Channel Therapeutics Corporation operates as a clinical-stage biotechnology company, committed to the entire process of identifying, advancing, and bringing to market novel therapies aimed at reducing pain. Its research strategy centers on precisely inhibiting the NaV1.7 sodium ion-channel, in addition to other related receptors within the broader NaV family. The firm's flagship investigational drug, CC8464, is currently undergoing Phase 2a clinical evaluation.